A First-in-Class Chemical-Induced Proximity System Achieves Dose-Dependent Control of Tumor Protein P53 Gene Activation in Preclinical Models of Gastric Cancer
- 8 September 2025
- journal article
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 8 (10) , 3585-3599
Abstract
The tumor protein P53 (TP53) gene has long been studied in cancer research with genomic and epigenetic aberrations playing a driving role in cancer pathology, yet even after decades of work, only a few methods have been developed to specifically target TP53 therapeutically. Some cancers are driven by loss-of-function TP53 mutations, while others have wild-type TP53 in a transcriptionally repressed state; the latter is exploitable by advances in epigenome editing. In our previous work, we demonstrated that deactivated CRISPR/Cas9 systems (dCas9), combined with an FK-506-binding protein (FKBP) recruitment protein tag and chemical epigenetic modifier (CEM) small molecules, can elicit gene-specific changes in expression in a dose-dependent manner. Here, we describe the development, application, and characterization of the dCas9-FKBP-CEM technology to increase TP53 expression. We demonstrate that catalyzing increased TP53 expression via dCas9-FKBP-CEM87 induced apoptosis, cell cycle arrest, and tumor growth inhibition in a dose-dependent manner in preclinical models of gastric cancer.Keywords
Funding Information
- Icahn School of Medicine at Mount Sinai
- American Cancer Society (RSG-21-091-01)
- National Institute of General Medical Sciences (R35GM148365, R41GM146326)
This publication has 69 references indexed in Scilit:
- Gene therapy clinical trials, where do we go? An overviewBiomedicine & Pharmacotherapy, 2022
- A CRISPR/dCasX‐mediated transcriptional programming system for inhibiting the progression of bladder cancer cells by repressing c‐MYC or activating TP53Clinical and Translational Medicine, 2021
- Update on gastric cancer treatments and gene therapiesCancer and Metastasis Reviews, 2019
- Design of small molecule epigenetic modulatorsBioorganic & Medicinal Chemistry Letters, 2014
- Drugging the undruggable: Transcription therapy for cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2013
- A Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53Cancer Cell, 2010
- Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature reviewInternational Journal of Cancer, 2010
- Lentiviral Vectors in Gene Therapy: Their Current Status and Future PotentialArchivum Immunologiae et Therapiae Experimentalis, 2010
- Cisplatin-Induced Growth Arrest of Head and Neck Cancer Cells Correlates With Increased Expression of p16 and p53JAMA Otolaryngology–Head & Neck Surgery, 2006
- The p53 pathway and human cancerBritish Journal of Surgery, 2005